Cargando…

Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients

OBJECTIVE: The aim of this study was to assess the prognostic and predictive values of circulating tumor cell (CTC) analysis in colorectal cancer patients. PATIENTS AND METHODS: Presence of CTCs was evaluated in 60 colorectal cancer patients before systemic therapy - from which 33 patients were also...

Descripción completa

Detalles Bibliográficos
Autores principales: de Albuquerque, Andreia, Kubisch, Ilja, Stölzel, Ulrich, Ernst, Dominikus, Boese-Landgraf, Joachim, Breier, Georg, Stamminger, Gudrun, Fersis, Nikos, Kaul, Sepp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508882/
https://www.ncbi.nlm.nih.gov/pubmed/23146106
http://dx.doi.org/10.1186/1479-5876-10-222
_version_ 1782251247385968640
author de Albuquerque, Andreia
Kubisch, Ilja
Stölzel, Ulrich
Ernst, Dominikus
Boese-Landgraf, Joachim
Breier, Georg
Stamminger, Gudrun
Fersis, Nikos
Kaul, Sepp
author_facet de Albuquerque, Andreia
Kubisch, Ilja
Stölzel, Ulrich
Ernst, Dominikus
Boese-Landgraf, Joachim
Breier, Georg
Stamminger, Gudrun
Fersis, Nikos
Kaul, Sepp
author_sort de Albuquerque, Andreia
collection PubMed
description OBJECTIVE: The aim of this study was to assess the prognostic and predictive values of circulating tumor cell (CTC) analysis in colorectal cancer patients. PATIENTS AND METHODS: Presence of CTCs was evaluated in 60 colorectal cancer patients before systemic therapy - from which 33 patients were also evaluable for CTC analysis during the first 3 months of treatment - through immunomagnetic enrichment, using the antibodies BM7 and VU1D9 (targeting mucin 1 and EpCAM, respectively), followed by real-time RT-PCR analysis of the tumor-associated genes KRT19, MUC1, EPCAM, CEACAM5 and BIRC5. RESULTS: Patients were stratified into groups according to CTC detection (CTC negative, when all marker genes were negative; and CTC positive when at least one of the marker genes was positive). Patients with CTC positivity at baseline had a significant shorter median progression-free survival (median PFS 181.0 days; 95% CI 146.9-215.1) compared with patients with no CTCs (median PFS 329.0 days; 95% CI 299.6-358.4; Log-rank P < .0001). Moreover, a statistically significant correlation was also founded between CTC detection during treatment and radiographic findings at the 6 month staging. This correlation applied to CTC results before therapy (odds ratio (OR), 6.22), 1 to 4 weeks after beginning of treatment (OR, 5.50), 5 to 8 weeks after beginning of treatment (OR, 7.94) 9 to 12 weeks after beginning of treatment (OR, 14.00) and overall CTC fluctuation during the course of treatment (OR, 20.57). CONCLUSION: The present study provides evidence of a strong correlation between CTC detection and radiographic disease progression in patients receiving chemotherapy for colorectal cancer. Our results suggest that in addition to the current prognostic factors, CTC analysis represent a potential complementary tool for prediction of colorectal cancer patients’ outcome. Moreover, the present test allows for molecular characterization of CTCs, which may be of relevance to the creation of personalized therapies.
format Online
Article
Text
id pubmed-3508882
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35088822012-11-29 Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients de Albuquerque, Andreia Kubisch, Ilja Stölzel, Ulrich Ernst, Dominikus Boese-Landgraf, Joachim Breier, Georg Stamminger, Gudrun Fersis, Nikos Kaul, Sepp J Transl Med Research OBJECTIVE: The aim of this study was to assess the prognostic and predictive values of circulating tumor cell (CTC) analysis in colorectal cancer patients. PATIENTS AND METHODS: Presence of CTCs was evaluated in 60 colorectal cancer patients before systemic therapy - from which 33 patients were also evaluable for CTC analysis during the first 3 months of treatment - through immunomagnetic enrichment, using the antibodies BM7 and VU1D9 (targeting mucin 1 and EpCAM, respectively), followed by real-time RT-PCR analysis of the tumor-associated genes KRT19, MUC1, EPCAM, CEACAM5 and BIRC5. RESULTS: Patients were stratified into groups according to CTC detection (CTC negative, when all marker genes were negative; and CTC positive when at least one of the marker genes was positive). Patients with CTC positivity at baseline had a significant shorter median progression-free survival (median PFS 181.0 days; 95% CI 146.9-215.1) compared with patients with no CTCs (median PFS 329.0 days; 95% CI 299.6-358.4; Log-rank P < .0001). Moreover, a statistically significant correlation was also founded between CTC detection during treatment and radiographic findings at the 6 month staging. This correlation applied to CTC results before therapy (odds ratio (OR), 6.22), 1 to 4 weeks after beginning of treatment (OR, 5.50), 5 to 8 weeks after beginning of treatment (OR, 7.94) 9 to 12 weeks after beginning of treatment (OR, 14.00) and overall CTC fluctuation during the course of treatment (OR, 20.57). CONCLUSION: The present study provides evidence of a strong correlation between CTC detection and radiographic disease progression in patients receiving chemotherapy for colorectal cancer. Our results suggest that in addition to the current prognostic factors, CTC analysis represent a potential complementary tool for prediction of colorectal cancer patients’ outcome. Moreover, the present test allows for molecular characterization of CTCs, which may be of relevance to the creation of personalized therapies. BioMed Central 2012-11-13 /pmc/articles/PMC3508882/ /pubmed/23146106 http://dx.doi.org/10.1186/1479-5876-10-222 Text en Copyright ©2012 de Albuquerque et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
de Albuquerque, Andreia
Kubisch, Ilja
Stölzel, Ulrich
Ernst, Dominikus
Boese-Landgraf, Joachim
Breier, Georg
Stamminger, Gudrun
Fersis, Nikos
Kaul, Sepp
Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
title Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
title_full Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
title_fullStr Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
title_full_unstemmed Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
title_short Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
title_sort prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508882/
https://www.ncbi.nlm.nih.gov/pubmed/23146106
http://dx.doi.org/10.1186/1479-5876-10-222
work_keys_str_mv AT dealbuquerqueandreia prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT kubischilja prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT stolzelulrich prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT ernstdominikus prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT boeselandgrafjoachim prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT breiergeorg prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT stammingergudrun prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT fersisnikos prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients
AT kaulsepp prognosticandpredictivevalueofcirculatingtumorcellanalysisincolorectalcancerpatients